The efficacy and safety of cyclosporine reduction in de novo renal allograft patients receiving sirolimus and corticosteroids: results from an open‐label comparative study

Publisher： John Wiley & Sons Inc

E-ISSN： 1432-2277|27|2|176-186

ISSN： 0934-0874

Source： TRANSPLANT INTERNATIONAL (ELECTRONIC), Vol.27, Iss.2, 2014-02, pp. : 176-186

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

An Open-Label Extension Study to Evaluate Safety and Efficacy of Pazopanib in Patients with Advanced Renal Cell Carcinoma

By  

Oncology, Vol. 87, Iss. 6, 2014-09 ,pp. : 342-350

Karger

Access to resources Recommend Favorite

A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis

By Finn William F.   Joy Melanie S.    

Current Medical Research and Opinion, Vol. 21, Iss. 5, 2005-05 ,pp. : 657-664

Informa Healthcare

Access to resources Recommend Favorite

Pharmacokinetics, Efficacy and Safety of IMMUNATE® Solvent/Detergent (IMMUNATE® S/D) in Previously Treated Patients with Severe Hemophilia A: Results of a Prospective, Multicenter, Open-Label Phase III Study

By  

Acta Haematologica, Vol. 119, Iss. 2, 2008-02 ,pp. : 89-97

Karger

Access to resources Recommend Favorite

Results of a phase I/II open‐label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients

By  

HAEMOPHILIA, Vol. 21, Iss. 6, 2015-11 ,pp. : 784-790

John Wiley & Sons Inc

Access to resources Recommend Favorite

Long‐term patient‐reported outcomes from an open‐label safety and efficacy study of bosutinib in Philadelphia chromosome–positive chronic myeloid leukemia patients resistant or intolerant to prior therapy

By  

CANCER, Vol. 124, Iss. 3, 2018-02 ,pp. : 587-595

John Wiley & Sons Inc

Access to resources Recommend Favorite